Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, Philipp Kiewe, Karin Mayer, Jörg Chromik, Markus Radsak, Thomas Wolff, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie, Aristoteles Giagounidis
Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung
263Zitate
(Scopus)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study“. Zusammen bilden sie einen einzigartigen Fingerprint.